Jane E. Latz

774 total citations
28 papers, 664 citations indexed

About

Jane E. Latz is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Jane E. Latz has authored 28 papers receiving a total of 664 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Pulmonary and Respiratory Medicine, 22 papers in Oncology and 6 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Jane E. Latz's work include Lung Cancer Treatments and Mutations (23 papers), Neutropenia and Cancer Infections (10 papers) and Acute Lymphoblastic Leukemia research (6 papers). Jane E. Latz is often cited by papers focused on Lung Cancer Treatments and Mutations (23 papers), Neutropenia and Cancer Infections (10 papers) and Acute Lymphoblastic Leukemia research (6 papers). Jane E. Latz collaborates with scholars based in United States, Japan and France. Jane E. Latz's co-authors include Robert D. Johnson, Atalanta Ghosh, Ajai K. Chaudhary, James J. Rusthoven, Mats O. Karlsson, Chris H. Takimoto, Eric K. Rowinsky, Kazuhiko Nakagawa, Anthony W. Tolcher and Amita Patnaik and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and British Journal of Cancer.

In The Last Decade

Jane E. Latz

28 papers receiving 661 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jane E. Latz United States	14	447	391	131	81	52	28	664
Meredith K. Chuk United States	14	260 0.6×	429 1.1×	175 1.3×	54 0.7×	116 2.2×	29	858
N. J. Vogelzang United States	16	290 0.6×	302 0.8×	286 2.2×	25 0.3×	89 1.7×	38	759
L. Cals France	15	253 0.6×	495 1.3×	79 0.6×	27 0.3×	102 2.0×	41	674
V.J. Harvey New Zealand	11	176 0.4×	319 0.8×	226 1.7×	72 0.9×	77 1.5×	24	678
Vittorio Franciosi Italy	17	470 1.1×	533 1.4×	160 1.2×	61 0.8×	131 2.5×	37	809
Kenichi Gemba Japan	19	837 1.9×	395 1.0×	163 1.2×	53 0.7×	46 0.9×	68	1.1k
Shiven B. Patel United States	12	168 0.4×	276 0.7×	106 0.8×	46 0.6×	41 0.8×	47	420
Gabriel Tinoco United States	11	184 0.4×	232 0.6×	142 1.1×	20 0.2×	97 1.9×	52	576
R. Smith United States	4	830 1.9×	722 1.8×	186 1.4×	33 0.4×	138 2.7×	5	1.1k
A. McDonald United Kingdom	14	203 0.5×	409 1.0×	210 1.6×	40 0.5×	127 2.4×	19	721

Countries citing papers authored by Jane E. Latz

Since Specialization

Citations

This map shows the geographic impact of Jane E. Latz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jane E. Latz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jane E. Latz more than expected).

Fields of papers citing papers by Jane E. Latz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jane E. Latz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jane E. Latz. The network helps show where Jane E. Latz may publish in the future.

Co-authorship network of co-authors of Jane E. Latz

This figure shows the co-authorship network connecting the top 25 collaborators of Jane E. Latz. A scholar is included among the top collaborators of Jane E. Latz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jane E. Latz. Jane E. Latz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Clément-Duchêne, Christelle, Ronald B. Natale, Thierry Jahan, et al.. (2012). A phase II study of enzastaurin in combination with erlotinib in patients with previously treated advanced non-small cell lung cancer. Lung Cancer. 78(1). 57–62. 11 indexed citations

Padda, Sukhmani K., et al.. (2011). A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 69(4). 1013–1020. 5 indexed citations

Harb, Wael A., Daniel S. Bradford, José A. Bufill, et al.. (2010). Randomized, Double-Blinded, Multicenter, Phase II Study of Pemetrexed, Carboplatin, and Bevacizumab with Enzastaurin or Placebo in Chemonaïve Patients with Stage IIIB/IV Non-small Cell Lung Cancer: Hoosier Oncology Group LUN06-116. Journal of Thoracic Oncology. 5(11). 1815–1820. 23 indexed citations

Dickgreber, Nicolas, Jens Benn Sørensen, Tine Schytte, et al.. (2010). Pemetrexed Safety and Pharmacokinetics in Patients with Third-Space Fluid. Clinical Cancer Research. 16(10). 2872–2880. 18 indexed citations

Harb, Wael A., Daniel S. Bradford, José A. Bufill, et al.. (2009). Randomized, double blind, multicenter, phase II study of pemetrexed (PEM), carboplatin (CARBO), bevacizumab (BEV) with enzastaurin (ENZ) or placebo (PBO) in chemotherapy-naive patients with stage IIIB/IV non-small cell lung cancer (NSCLC): Hoosier Oncology Group (HOG) LUN06–116. Journal of Clinical Oncology. 27(15_suppl). 8035–8035. 8 indexed citations

Specenier, Pol, Tudor–Eliade Ciuleanu, Jane E. Latz, et al.. (2008). Pharmacokinetic evaluation of platinum derived from cisplatin administered alone and with pemetrexed in head and neck cancer patients. Cancer Chemotherapy and Pharmacology. 64(2). 233–241. 14 indexed citations

Paridaens, Robert, Luc Dirix, Herlinde Dumez, et al.. (2007). Phase I/II Pharmacokinetic Study of Pemetrexed and Epirubicin in Patients with Locally Advanced or Metastatic Breast Cancer. Clinical Breast Cancer. 7(11). 861–866. 5 indexed citations

Latz, Jane E., Susumu Adachi, James T. Symanowski, et al.. (2007). PD4-3-4: Correlation of pemetrexed (PEM) NSCLC exposure-response relationships (ERRs) to clinical study results from western and Japanese patient populations. Journal of Thoracic Oncology. 2(8). S455–S456. 6 indexed citations

Takimoto, Chris H., Jane E. Latz, Leonardo Forero, et al.. (2007). Phase I and Pharmacokinetic Study of Pemetrexed with High-Dose Folic Acid Supplementation or Multivitamin Supplementation in Patients with Locally Advanced or Metastatic Cancer. Clinical Cancer Research. 13(9). 2675–2683. 44 indexed citations

10.

Nakagawa, Kazuhiko, Satoshi Kudoh, Kunihiko Matsui, et al.. (2006). A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumours. British Journal of Cancer. 95(6). 677–682. 52 indexed citations

11.

Dittrich, Christian, Luboš Petruželka, P Vodvářka, et al.. (2006). A Phase I Study of Pemetrexed (ALIMTA) and Cyclophosphamide in Patients with Locally Advanced or Metastatic Breast Cancer. Clinical Cancer Research. 12(23). 7071–7078. 13 indexed citations

12.

Sweeney, Christopher J., Chris H. Takimoto, Jane E. Latz, et al.. (2006). Two Drug Interaction Studies Evaluating the Pharmacokinetics and Toxicity of Pemetrexed When Coadministered with Aspirin or Ibuprofen in Patients with Advanced Cancer. Clinical Cancer Research. 12(2). 536–542. 29 indexed citations

13.

Mita, Alain C., Christopher J. Sweeney, Sharyn D. Baker, et al.. (2006). Phase I and Pharmacokinetic Study of Pemetrexed Administered Every 3 Weeks to Advanced Cancer Patients With Normal and Impaired Renal Function. Journal of Clinical Oncology. 24(4). 552–562. 90 indexed citations

14.

Latz, Jane E., Ajai K. Chaudhary, Atalanta Ghosh, & Robert D. Johnson. (2005). Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients. Cancer Chemotherapy and Pharmacology. 57(4). 401–411. 75 indexed citations

15.

Latz, Jane E., Mats O. Karlsson, James J. Rusthoven, Atalanta Ghosh, & Robert D. Johnson. (2005). A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapy. Cancer Chemotherapy and Pharmacology. 57(4). 412–426. 55 indexed citations

16.

Latz, Jane E., James J. Rusthoven, Mats O. Karlsson, Atalanta Ghosh, & Robert D. Johnson. (2005). Clinical application of a semimechanistic-physiologic population PK/PD model for neutropenia following pemetrexed therapy. Cancer Chemotherapy and Pharmacology. 57(4). 427–435. 43 indexed citations

17.

Misset, J. L., Érick Gamelin, Mario Campone, et al.. (2004). Phase I and pharmacokinetic study of the multitargeted antifolate pemetrexed in combination with oxaliplatin in patients with advanced solid tumors. Annals of Oncology. 15(7). 1123–1129. 26 indexed citations

18.

Nakagawa, Ken, Satoshi Kudoh, Kunihiko Matsui, et al.. (2004). 486 A phase I study of pemetrexed supplemented with folic acid (FA) and vitamin b12 (VB12) in Japanese patients with solid tumors. European Journal of Cancer Supplements. 2(8). 148–148. 4 indexed citations

19.

Pivot, Xavier, Éric Raymond, Brigitte Laguerre, et al.. (2001). Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck. British Journal of Cancer. 85(5). 649–655. 67 indexed citations

20.

Cherner, Jay A., et al.. (1989). Comparison of nizatidine and cimetidine as once-nightly treatment of acute duodenal ulcer. Nizatidine Multicenter Duodenal Ulcer Study Group.. PubMed. 84(7). 769–74. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact